tbuckley/cabot-search huggingface dataset:
Abstract 3743: Bioluminescent, non-lytic, real-time cell viability assay
Authors: Sarah J. Duellman, Jolanta Vidugiriene, Wenhui Zhou, Jean Osterman, Ruslan Arbit, Laurent Bernad, Poncho Meisenheimer, James J. Cali
Journal: Cancer Research (2014)

Abstract Cell-based assay development for cancer drug discovery continues to advance toward more innovative methods that provide efficient workflow and meaningful data. Rapid, sensitive techniques that are non-lytic and therefore facilitate multiplexing with a wide range of assays allow more data to be gained per well and conserve precious samples. Real time measurement of cell viability also allows numerous measurements over time without the need for separate plates at each time point. Real time measurements allow unique analyses including interrogation of the timing of drug killing, identification of static vs toxic drug effects, and determination of the ideal time to multiplex an additional assay. Cancer drug discovery would benefit from novel assay technologies that allow real time measurements with multiplexing capability. We have developed a homogeneous, non-lytic, and bioluminescent method to analyze cell viability in real time through measurement of the reducing potential of the cell. The signal correlates with the number of viable cells making it well-suited for cytotoxicity studies. This Real Time Cell Viability Assay utilizes the NanoLuc luciferase enzyme, which is 100-fold brighter than either firefly (Photinus pyralis) or Renilla reniformis luciferase, and the novel substrate, furimazine. Together these reagents produce high intensity luminescence through an ATP-independent reaction. The assay can be performed in two formats, live cell endpoint or continuous read. The live cell endpoint method is sensitive, rapid, and enables extensive multiplexing opportunities due to the non-lytic measurement and signal depletion upon cell lysis. When the assay is set up in the continuous read format, the cell viability reagents can be added at the same time as cell plating, drug dosing, or at whatever point in the assay the researcher would like to start obtaining viability readings. The luminescent signal can be continually monitored from the same wells over an extended period of time to analyze cell viability in real time. This real time cell viability assay enables non-lytic cell viability measurements, extensive multiplexing options including both fluorescent and luminescent assays with no special filter requirements, straightforward normalization studies, conservation of precious samples and reagents, and a sensitive, real time measurement of cell viability. Citation Format: Sarah J. Duellman, Jolanta Vidugiriene, Wenhui Zhou, Jean Osterman, Ruslan Arbit, Laurent Bernad, Poncho Meisenheimer, James J. Cali. Bioluminescent, non-lytic, real-time cell viability assay. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3743. doi:10.1158/1538-7445.AM2014-3743
Abstract 16734: Il-10-Inhibit Pressure Overload-Induced Proliferation and Differentiation of Fibroblast Progenitor Cells and Thus Improve Cardiac Function
Authors: Suresh K Verma, Prasanna Krishnamurthy, David Barefield, Venkata N Garikipati, Mohsin Khan, Alexander R Mackie, Tatiana V Abramova, Veronica Ramirez, Cynthia Benedict, Jennifer Johnson, Emily Nicoloff, Sakthivel Sadayappan, Gangjian Qin, Walter J Koch, Raj Kishore
Journal: Circulation (2014)

Background: Recently we have shown that IL-10, an anti-inflammatory cytokine, markedly inhibited the pressure overload-induced cardiac fibrosis, however, antifibrotic mechanisms of IL-10 are largely unknown. In most organs, including heart, activated fibroblast play critical role in extracellular matrix remodeling, however, very little information is available regarding the origin of myoFBs. Here we hypothesized that IL-10 inhibits stress-induced proliferation and differentiation of nonresident bone marrow-derived fibroblast progenitor cells and therefore, attenuates cardiac fibrosis and improves of heart function.

Methods and Results: Cardiac hypertrophy was induced in Wild-type (WT) and IL-10-knockout (KO) mice by transverse aortic constriction (TAC). TAC-induced left ventricular (LV) dysfunction and fibrosis were further exaggerated in KO mice compared to WT. TAC significantly increased TGF-β, collagen Iα and IIIα genes expression. Systemic recombinant mouse IL-10 administration markedly improved LV function, inhibited TAC-induced cardiac fibrosis and fibrosis associated genes expression. To identify the role of fibroblast progenitor cells (FPCs), we measured the mobilization of FPCs (Prominin1 positive cells) from bone marrow to heart by FACs. Exacerbated mobilization of FPCs in peripheral blood and heart in IL-10 KO mice were found 3 and 7 days after aortic constriction. Bone marrow transplantation experiments were performed where WT-GFP positive marrow was transplanted in BM depleted IL-10 KO mice. TAC-induced mobilization was significantly reduced in WT-transplanted marrow as compare to TAC-IL-10 KO mice. To identify the role IL-10 on TGFβ-induced endothelial cells trans-differentiation to myofibroblasts, we treated aortic endothelial cells with IL-10 and TGFβ2 for 96 hrs. Both Immunocytochemistry and Western blot analysis results suggested that TGF-β2-induced EndMT was significantly inhibited by IL-10 treatment. To understand the mechanisms, we found that TGF-β2-induced Notch1 signaling was reduced by IL-10.

Conclusion: Taken together our observations suggest that the anti-fibrotic effects of IL-10 treatment are mediated by reduced proliferation and differentiation of non-resident myofibroblasts.
Sexual dysfunction in college men and women
Authors: A Werner
Journal: American Journal of Psychiatry (1975)

The author presents data and illustrative excerpts from 1,000 letters relating to health and personal concerns that were sent to his column in a college newspaper. There were 532 letters expressing sexual concerns, 65 percent of which raised questions about anatomy and physiology. A comparison of the distribution of problems of sexual dysfunction in this study with that of an earlier study involving older patients showed very different distributions. The author points out the need for sex counseling and education for young people who are sexually active and discusses the unique problems involved in treating this population.
Holding the Bag
Authors: S J Lurie
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Impact of a Comprehensive Heart Failure Management Program on Hospital Readmission and Functional Status of Patients With Advanced Heart Failure
Authors: Gregg C Fonarow, Lynne W Stevenson, Julie A Walden, Nancy A Livingston, Anthony E Steimle, Michele A Hamilton, Jaime Moriguchi, Jan H Tillisch, Mary A Woo
Journal: Journal of the American College of Cardiology (1997)
PERICARDITIS WITH EFFUSION COMPLICATING TULAREMIA
Authors: D. D. Stofer
Journal: Annals of Internal Medicine (1938)

Case Reports1 September 1938PERICARDITIS WITH EFFUSION COMPLICATING TULAREMIAD. D. STOFER, A.B., M.D., F.A.C.P.D. D. STOFER, A.B., M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-12-3-407 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptBecause of the fact that tularemia is somewhat rare, its complications are not fully known. The purpose of this paper is to report the recovery of a case of tularemia in which pericarditis with effusion occurred as a complication. A search of the literature in the Surgeon General's Library and other available sources reveals but one other case of this kind. Pessin1(1936) reported a case of pericarditis with effusion complicating tularemia, which was diagnosed a few days before death of the patient and verified by autopsy findings. The clinical findings in his case as well as in this one...Reference1. PESSIN SB: Tularemic pneumonia, pericarditis and ulcerative stomatitis, Arch. Int. Med., 1936, lvii, 1125. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Kansas City, Missouri*Received for publication August 2, 1937. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byErkrankungen des PerikardTularemic PericarditisTULAREMIC PERICARDITIS: A REPORT OF TWO CASES INCLUDING ONE OF CONSTRICTIVE PERICARDITIS*H. CLARKSON MEREDITH JR., M.D. 1 September 1938Volume 12, Issue 3Page: 407-412KeywordsAutopsyLibrariesSurgeonsTularemia ePublished: 1 December 2008 Issue Published: 1 September 1938 PDF downloadLoading ...
Consumer group criticises surgeon general on ECT
Authors: James Ciment
Journal: BMJ (1999)

Although still in preliminary draft form and yet to be released officially to the public, the long awaited US surgeon general's report on mental health has already created an uproar, after a consumer health group released excerpts highlighting the efficacy and safety of electroconvulsive therapy (ECT) in the treatment of depression.

According to the draft report, which cites several clinical studies published between 1993 and 1997, electroconvulsive therapy “is regarded as a safe and effective treatment for depression and …
Abstract 11535: A Triple-Targeting Strategy for Characterization of Plaque Inflammation in Mice and Humans Using Molecular Imaging
Authors: Marvin Krohn-Grimberghe, Katharina Bartmann, Hannes Hummel, Irene Neudorfer, Dominik von Elverfeldt, Annette Merkle, Bettina Wernli, Joachim Schoellhorn, Meinrad Gawaz, Christoph Bode, Constantin von zur Muhlen
Journal: Circulation (2014)

Introduction: Molecular imaging using inflammatory markers might offer additional information for plaque characterization. Here, we present a novel triple-target imaging strategy for the diagnosis and characterization of inflamed plaques using antibodies against vascular cell adhesion molecule 1 (VCAM1), lectin-like ox-LDL receptor (LOX1), and glycoprotein VI (GPVI). Methods: Antibodies against VCAM1, LOX1, GPVI, as well as control antibodies were conjugated to three different fluorescent dyes for imaging with the IVIS spectrum. As a model of atherosclerosis, we used ApoE-/- mice which were divided into three groups and fed 3 months of western type diet (WTD), 6 months of WTD, or 3 months of WTD with daily high-dose atorvastatin, respectively. Afterwards, their aortic arches were removed and imaged after incubation with the antibodies. To transfer our findings into a human model, we use carotid endarterectomy specimens for IVIS as well as magnetic resonance imaging (MRI). For MRI, we coupled our antibodies to microparticles of iron oxide (MPIO), a hypo intense contrast agent, and imaged the plaques using a small animal 9.4 T MRI after incubation under flow conditions. Results: The VCAM1, LOX1, and GPVI antibody constructs showed specific binding to atherosclerotic plaques in mice (p&lt;0.05 for all three; n=4-5 per group) at both time points in comparison with their controls. The additional treatment with Atorvastatin led to a reduction for the signals of all three receptors (all p&lt;0.05). After 6 in comparison to 3 month of WTD, an increase of LOX1 (p&lt;0.05), a reduction of VCAM1 (p&lt;0.05) and no significant changes of GPVI (p=0,81) were seen. Perfusion of the endarterectomy specimens with the MPIO-labeled contrast agent led to a significant signal reduction in MRI in comparison with their controls (n=8 per group; VCAM1 p=0.02; GPVI p=0.03). Our preliminary data for LOX1 show a tendency towards reduction (n=4; p=0.15) while not reaching significance yet. Conclusion: In this approach, we apply a new strategy of molecular MRI by targeting three different inflammatory markers in murine and human atherosclerosis for the noninvasive characterization of this disease, which might help to improve early detection and therapy of vulnerable atherosclerotic plaques.
Abstract 16024: Elevated Bacterial Levels Measured by 16s rRNA PCR Correlate With Worsening Clinical Markers in Congestive Heart Failure
Authors: Joshua Weisbrot, Thomas S Parker, Stuart D Saal, Daniel M Levine, Suizhen Qui, Evelyn M Horn
Journal: Circulation (2014)

Background:  It is well established that patients with CHF have increased inflammatory markers such as TNF, IL-6 and CRP. These changes are prognostic on EF, progression to higher NYHA class and death. However, the physiological mechanisms that underlie the increased inflammation in CHF patients remain unresolved. In CHF, elevated vascular pressures in the pulmonary and gut microcirculation can lead to increased bacterial translocation, which in turn can activate the immune system. We hypothesized that subclinical bacteria modulates the immune response observed with CHF and correlate with severity of CHF.   Methods:  We studied 50 patients recruited from our cardiology and advanced heart failure clinics. Patients with active infections were excluded. A hybridization capture probe to selectively reduce interference from human DNA and PCR were used to detect DNA from the bacterial 16S rRNA gene. This method detects bacteria that do not grow in culture including partially degraded bacteria within circulating immune cells. Inflammatory markers were measured to study whether bacterial and cytokine levels correlate with various clinical parameters including NYHA class, EF and filling pressures.   Results:  We found that patients with NYHA class III-IV symptoms have significantly higher bacterial levels, IL-6 and CRP compared to patients with NYHA class I-II symptoms. Patients with EF less than 25% have significantly higher bacterial levels and TNF than patients with EF greater than 25%.  We also found that bacterial levels, IL6, TNF and CRP are positively correlated with NYHA class, lower EF, CVP, admission for CHF, RV dysfunction and elevated pulmonary artery pressure.   Conclusions:  Our results show that bacterial levels measured by 16s ribosomal RNA PCR correlate with increased cytokine production and clinical markers of CHF. These findings suggest that subclinical bacteria and immune activation may serve as potential clinical targets in worsening heart failure.
The Nature of Man. Studies in Optimistic Philosophy.
Authors: Élie Metchnikoff
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Parental perceptions of the informed consent process in pediatric bone marrow transplantation (BMT)
Authors: J. M. Benedict, C. Simpson, C. V. Fernandez
Journal: Journal of Clinical Oncology (2004)

6123 Background: The validity of informed consent in pediatric bone marrow transplantation (BMT) may be compromised by the complexity of information provided and the emotional duress under which it occurs. Anecdotal evidence suggests parents feel compelled to consent to BMT on behalf of their child. The purpose of this study was: 1. to determine if parents perceive there to be a real/actual choice when consenting to pediatric BMT, 2. to survey parental experience of the informed consent process, and 3. to determine if the informed consent process affects parental hope, anxiety, stress or guilt. Methods: An information package and informed consent document were mailed to 67 English-speaking parents of 34 children who underwent BMT. They were all prepared for transplant by one physician using a standardized template at the IWK Health Centre (Halifax, Nova Scotia, Canada) between 1998 and 2002. Semi-structured interviews were conducted by phone (13) or in person (7). Transcripts were analyzed for common themes by 2 independent reviewers. Results: Twenty parents (12 mothers and 8 fathers) of 12 children consented to participate in the study. This included five parents of three children who had died. Parental participants did not differ from eligible non-participants in indication for transplant, donor source, major complications, or death rates for their children. All subjects reported feeling they had no personal choice but to consent to BMT. Parents denied experiencing external pressure to consent. Subjects felt well prepared for potential side effects and complications; only 2 reported unexpected side effects. Parents did not report retrospectively doubting the informed consent process. All parents would consent to pediatric BMT if in the same position again. Parental hope, stress, guilt and anxiety were not reported to be affected by the informed consent process. Conclusions: Parents do not perceive a personal choice when providing consent for pediatric BMT. Regardless of outcome, parents do not retrospectively question the quality of consent they provided for pediatric BMT nor do they feel that hope, stress, guilt or anxiety are affected by the consent process. No significant financial relationships to disclose.
Positron Emission Tomography to Evaluate Lung Lesions—Reply
Authors: Michael K. Gould
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Single Molecules Meet Genomics
Authors: Xiaoliang Sunney Xie
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 16976: A Mouse Model of Human Congenital Heart Disease: High Incidence of Diverse Cardiac Anomalies, Ventricular Noncompaction and Progressive Atrioventricular Block by Heterozygous Nkx2-5 Homeodomain Missense Mutation
Authors: Michelle Melanson, Hassan Ashraf, Rajib Chowdhury, Michael Silberbach, Hiroko Wakimoto, D.Woodrow Benson, Robert Anderson, Hideko Kasahara
Journal: Circulation (2014)

Introduction: Heterozygous human NKX2-5 mutations are highly penetrant and associated with varied congenital heart defects (CHD) as well as progressive postnatal atrioventricular (AV) block, usually requiring pacemaker implantation. Heterozygous knockout of murine Nkx2-5, in contrast, manifests less profound CHD with low disease penetrance. Hypothesis: We hypothesized that heterozygous knock-in having a disease-causing missense mutation rather than heterozygous knockout will mimic the phenotype of human patients. Methods: Homeodomain (HD, DNA binding domain) missense mutations are the most frequently reported type of human NKX2-5 mutation, thus we replicated this genetic defect in a murine knock-in model (Arg52Gly) in a 129/Sv genetic background. Mouse phenotype was analyzed by histopathology (serial tissue sectioning, immunostaining), surface and telemetry ECG, and in vivo electrophysiology and compared to control Nkx2-5+/+ or Nkx2-5+/- mice at different postnatal stages from neonatal to 17 months of age...